FA
BMY.RT

FCG Advisors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

FCG Advisors’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$2.81M Buy
1,250,379
+6,768
+0.5% +$19.3K 0.66% 26
2020
Q2 		$4.45M Sell
1,243,611
-860
-0.1% -$3.1K 1.16% 16
2020
Q1 		$4.73M Buy
1,244,471
+970,603
+354% +$3.2M 1.35% 14
2019
Q4 		$824K Buy
+273,868
New +$712K 0.24% 61

Other funds holding BMY.RT

LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FCG Advisors's BMY.RT Position: Q3 2020 in Review

FCG Advisors increased its Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) stake by 0.54% in Q3 2020, buying an estimated $19.3K and bringing the position to 1,250,379 shares worth $2.81M. The position accounts for 0.66% of the portfolio, ranked #26.

FCG Advisors first reported a position in BMY.RT in Q4 2019 and has held it in 4 quarters since. The position peaked at $4.73M in Q1 2020. 571 funds tracked by Wall St. Rank hold BMY.RT as of Q3 2020.

  • FCG Advisors held 1,250,379 shares of Bristol-Myers Squibb Company Contingent Value Rights worth $2.81M as of Q3 2020.
  • FCG Advisors bought 6,768 Bristol-Myers Squibb Company Contingent Value Rights shares in Q3 2020, an estimated $19.3K.
  • Bristol-Myers Squibb Company Contingent Value Rights made up 0.66% of FCG Advisors's portfolio in Q3 2020, its #26 holding.
  • FCG Advisors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and has held it in 4 quarters since.
  • FCG Advisors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $4.73M in Q1 2020.
  • 571 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q3 2020.

Based on FCG Advisors's 13F filing for Q3 2020, filed 13 Nov 2020.